Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer

Recruiting now · Phase 2

Conditions studied: Advanced Breast Cancer

In brief

This is a prospective, randomised, controlled, multicentre study to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab (QL1706) in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer.

Key facts

Study ID

NCT07180160

Run by

Wenjin Yin

People needed

123

Starts

2025-09-25

Expected to finish

2028-03-01

Last updated by the study team

2025-11-18

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Female, age≥18 years old
• Expected survival ≥12 weeks
• ECOG 0-1
• Pathologically confirmed recurrent or metastatic breast cancer not amenable to curative surgery
• ER and/or PR positive, HER2 negative
• At least one measurable lesion or bone-only disease (osteolytic or mixed) according to RECIST v1.1
• Previously treated with ≤2 lines chemotherapy for advanced disease; previously treated with ≤2 CDK4/6 inhibitors
• Adequate organ function

You may not qualify if…

• During pregnancy and lactation
• Patients with central nervous system metastasis

Where it is running

• Renji Hospital, School of Medicine, Shanghai Jiaotong University — Shanghai, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.